Plasma-Based, Tumour-Informed MRD Analysis May Predict Recurrence During Adjuvant Osimertinib and Follow-Up in Resected, EGFR-mutated NSCLC By Ogkologos - April 2, 2025 637 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from an exploratory analysis of the ADAURA study Source RELATED ARTICLESMORE FROM AUTHOR FX-909 Demonstrates Acceptable Safety and Preliminary Antitumour Activity, Establishing a Proof of Concept for PPARγ Inverse Agonism in Advanced Urothelial Cancer Pimicotinib Shows Robust Antitumour Activity and Clinically Meaningful Improvements in Patients with Tenosynovial Giant Cell Tumour FDA Grants Accelerated Approval to Zongertinib for Unresectable or Metastatic Non-Squamous NSCLC MOST POPULAR How Wartime Violence Against Women Is Hurting Millions Worldwide August 2, 2021 COVID-19: “We’re having to rebuild and adapt because of coronavirus” July 15, 2020 Diagnosed Alone October 6, 2020 ESMO Calls for Concerted Action to Prevent Burnout and Foster Well-Being... September 10, 2024 Load more HOT NEWS Tratamiento agnóstico contra el cáncer: perspectiva de un experto Trastuzumab Deruxtecan Shows Promising Activity Among Patients with HER2-positive and Signal... The Obesity Paradox: It Increases Diabetes Risk But Can Help Cancer... Tackling under-representation of Black data scientists in cancer research
